Could a cheap arthritis drug prevent heart attacks?

NCT ID NCT07349875

Recruiting now Disease control Sponsor: Nanjing First Hospital, Nanjing Medical University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding low-dose colchicine (0.5 mg daily) to standard heart treatments can lower the risk of major heart problems like heart attacks and strokes. About 3,800 adults with stable coronary artery disease and non-flow-limiting plaque will be randomly assigned to get colchicine plus standard care or standard care alone. The goal is to see if colchicine's anti-inflammatory effects help protect the heart over up to 3 years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: colchicine
What this could lead to: If it works, this could provide a simple, low-cost way to lower the risk of heart attacks and strokes in people with stable coronary artery disease.
What could go wrong: This is a large phase 4 trial, but colchicine may cause side effects like stomach upset or liver issues. The benefit may be small or not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE (CAD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY ARTERY DISEASE (CAD)

Contacts and locations

Locations

Nanjing First Hospital
RECRUITING

Nanjing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.